Fig. 3.

Treatment change from primary surgery to use of neoadjuvant systemic therapy in 2020. (A) Predicted (corrected for total decline in diagnoses) and observed distribution of treatment schemes in 2020 per age group indicating the percent of patients with invasive breast cancer diagnosed in January-September 2020 who received each treatment scheme. (B) Difference between the observed and the corrected-predicted number of patients with invasive breast cancer diagnosed in January-September 2020 by treatment scheme and by month of incidence. Error bars represent 95% confidence intervals. When the 95% confidence interval does not contain 0, the observed number of cases is significantly different from what would be predicted if the number of patients receiving each treatment scheme declined (or increased) proportional to the total decline (or increase) in cases relative to the reference period. S = surgery. ST = systemic treatment (hormonal therapy, targeted therapy, chemotherapy). NAT = neoadjuvant systemic therapy. AT = adjuvant therapy (systemic and/or radiotherapy). Patients with multiple invasive or breast tumors were excluded from this analysis